Vivesto presents new Paccal Vet survival and safety data from dog hemangiosarcoma pilot study at VCS 2026
Bitget2026/09/24 06:03- Vivesto flagged newly reported topline results from two Paccal Vet studies for presentation at the Veterinary Cancer Society conference on Sept. 24.
- Dog pilot study in splenic hemangiosarcoma showed supportive survival and safety outcomes, reinforcing the case to move into a pivotal trial.
- Cat dose-escalation study indicated tolerability with early signs of single-agent anti-tumor activity; final results are expected in Q4 2026.
- Data were previously presented as topline results in September 2026; the conference posters provide an external forum for scientific review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
